Significant limitations associated with the analysis of human plasma soluble CD36 performed by ELISA

Violetta Dziedziejko, Natalia Pauli, Agnieszka Kuligowska, Krzysztof Safranow, Marta Goschorska, Dariusz Chlubek, Monika E. Rać



Introduction: Plasma sCD36 is generally considered to be a marker of macrophage activation and inflammation, accelerated fat accumulation in the vascular wall, and atherosclerosis.

The objective of the study is to develop a methodology for sCD36 determination.

Materials and methods: The material for sCD36 determination by ELISA assays was collected from fasting blood samples from healthy cases.

Results: The study identified possible problems in sCD36 plasma concentration measurement. The presented data also suggested that the interrelationship of sCD36 and various metabolic stimuli can significantly affect sCD36 plasma concentration.

Conclusion: The ELISA assay can be used to determine sCD36 concentration in human plasma.


sCD36 determination; plasma; ELISA; methodology


Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93(2):241-52. doi: 10.1016/S0092-8674(00)81575-5.

Nicholson AC, Frieda S, Pearce A, Silverstein RL. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines: evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol 1995;15(2):269-75. doi: 10.1161/01.ATV.15.2.269.

Nakagawa T, Nozaki S, Nishida M, Yakub JM, Tomiyama Y, Nakata A, et al. Oxidized LDL increases and interferon-γ decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 1998;18(8):1350-7. doi: 10.1161/01.ATV.18.8.1350.

Huh HY, Pearce SF, Yesner LM, Schindler JL, Silverstein RL. Regulated expression of CD36 during monocyte to macrophage differentiation: potential role of CD36 in foam cell formation. Blood 1996;87(5):2020-8.

Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R, McGregor JL. CD36 and macrophages in atherosclerosis. Cardiovasc Res 2007;75(3):468-77. doi: 10.1016/j.cardiores.2007.03.010.

Tuomisto TT, Riekkinen MS, Viita H, Levonen AL, Yla-Herttuala S. Analysis of gene and protein expression during monocyte-macrophage differentiation and cholesterol loading – cDNA and protein array study. Atherosclerosis 2005;180(2):283-91. doi: 10.1016/j.atherosclerosis.2004.12.023.

Love-Gregory L, Sherva R, Schappe T, Qi JS, McCrea J, Klein S, et al. Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile. Hum Mol Genet 2011;20(1):193-201. doi:10.1093/hmg/ddq449.

Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74. doi: 10.1038/nature01323.

Nicholson AC, Febbraio M, Han J, Silverstein RL, Hajjar DP. CD36 in atherosclerosis. The role of a class B macrophage scavenger receptor. Ann N Y Acad Sci 2000;902:128-31. doi: 10.1111/j.1749-6632.2000.tb06307.x.

Fernández-Real JM, Handberg A, Ortega F, Højlund K, Vendrell J, Ricart W. Circulating soluble CD36 is a novel marker of liver injury in subjects with altered glucose tolerance. J Nutr Biochem 2009;20(6):477-84. doi: 10.1016/j.jnutbio.2008.05.009.

Handberg A, Norberg M, Stenlund H, Hallmans G, Attermann J, Eriksson JW. Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. J Clin Endocrinol Metab 2010;95(4):1939-46. doi: 10.1210/jc.2009-2002.

Koonen DP, Jensen MK, Handberg A. Soluble CD36− a marker of the (pathophysiological) role of CD36 in the metabolic syndrome? Arch Physiol Biochem 2011;117(2):57-63. doi: 10.3109/13813455.2010.543136.

Glintborg D, Højlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008;31(2):328-34. doi: 10.2337/dc07-1424.

Handberg A, Levin K, Højlund K, Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation 2006;114(11):1169-76. doi: 10.1161/CIRCULATIONAHA.106.626135.

Chmielewski M, Bragfors-Helin AC, Stenvinkel P, Lindholm B, Anderstam B. Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients. Clin Chim Acta 2010;411:2079-82. doi: 10.1016/j.cca.2010.09.009.

Lykkeboe S, Larsen AL, Handberg A. Lack of consistency between two commercial ELISAs and against an in-house ELISA for the detection of CD36 in human plasma. Clin Chem Lab Med 2012;50(6):1071-4. doi: 10.1515/cclm-2011-0950.

Handberg A, Højlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, et al. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med 2012;271(3):294-304. doi: 10.1111/j.1365-2796.2011.02442.x.

Alkhatatbeh MJ, Enjeti AK, Acharya S, Thorne RF, Lincz LF. The origin of circulating CD36 in type 2 diabetes. Nutr Diabetes 2013;3:e59. doi: 10.1038/nutd.2013.1.

Liani R, Halvorsen B, Sestili S, Handberg A, Santilli F, Vazzana N, et al. Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free Radic Biol Med 2012;52(8):1318-24. doi: 10.1016/j.freeradbiomed.2012.02.012.

Handberg A, Skjelland M, Michelsen AE, Sagen EL, Krohg-Sørensen K, Russell D, et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke 2008;39(11):3092-5. doi: 10.1161/STROKEAHA.108.517128.

Alkhatatbeh MJ, Mhaidat NM, Enjeti AK, Lincz LF, Thorne RF. The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. J Thromb Haemost 2011;9(4):844-51. doi: 10.1111/j.1538-7836.2011.04220.x.


Copyright (c) 2018

License URL: